These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26786252)

  • 1. Anti-CD20 therapy and pauci-immune crescentic glomerulonephritis.
    Shu KH; Chiang WC; Chiu YL
    J Formos Med Assoc; 2017 Apr; 116(4):215-216. PubMed ID: 26786252
    [No Abstract]   [Full Text] [Related]  

  • 2. Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.
    Geetha D; Sethi S; De Vriese AS; Specks U; Kallenberg CGM; Lim N; Spiera R; St Clair EW; Merkel PA; Seo P; Monach PA; Lepori N; Fessler BJ; Langford CA; Hoffman GS; Sharma R; Stone JH; Fervenza FC;
    Am J Nephrol; 2017; 46(3):231-238. PubMed ID: 28881339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pauci-immune glomerulonephritis in children: a clinicopathologic study of 21 patients.
    Khalighi MA; Wang S; Henriksen KJ; Bock M; Keswani M; Chang A; Meehan SM
    Pediatr Nephrol; 2015 Jun; 30(6):953-9. PubMed ID: 25669759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANCA-positive pauci-immune rapidly progressive glomerulonephritis and the nephrotic syndrome.
    Jabur WL; Saeed HM
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):526-30. PubMed ID: 20427883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculitis: Rituximab: effective in ANCA-associated vasculitis?
    Schönermarck U; de Groot K
    Nat Rev Nephrol; 2011 Jan; 7(1):6-8. PubMed ID: 21173754
    [No Abstract]   [Full Text] [Related]  

  • 6. CMV gastric ulcer in a patient with pauci immune crescentic glomerulonephritis on rituximab - a rare combination.
    Ishtiaq R; Wilhelm DM; Ahmad S
    Postgrad Med; 2019 Nov; 131(8):619-622. PubMed ID: 31506001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An innovative approach to the treatment of immune-mediated glomerular diseases].
    Roccatello D
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement system activation in ANCA vasculitis: A translational success story?
    Kallenberg CG; Heeringa P
    Mol Immunol; 2015 Nov; 68(1):53-6. PubMed ID: 26597208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination.
    Hakroush S; Tampe B
    Front Immunol; 2021; 12():762006. PubMed ID: 34659268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the role of rituximab in ANCA GN: regressing toward the mean.
    Pendergraft WF; Falk RJ
    J Am Soc Nephrol; 2015 Apr; 26(4):771-4. PubMed ID: 25381425
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of antineutrophil cytoplasmic antibody-associated vasculitis with eicosapentaenoic acid.
    Hirahashi J; Jo A; Ueda K; Tojo A; Fujita T
    Ann Intern Med; 2012 May; 156(10):755-6. PubMed ID: 22586017
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-neutrophil cytoplasmic antibody positivity in five children with systemic lupus erythematosus--what is the importance of this finding?
    Bobek D; Vuković J; Malenica B; Bojanić K; Rukavina I; Jelušić M
    Acta Dermatovenerol Croat; 2014; 22(4):264-70. PubMed ID: 25580781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis.
    Shah S; Havill J; Rahman MH; Geetha D
    Clin Rheumatol; 2016 Apr; 35(4):953-60. PubMed ID: 26445939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 16. Pauci-immune necrotizing glomerulonephritis.
    Rutgers A; Sanders JS; Stegeman CA; Kallenberg CG
    Rheum Dis Clin North Am; 2010 Aug; 36(3):559-72. PubMed ID: 20688250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary for Patients: Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Ann Intern Med; 2020 Aug; 173(3):I18. PubMed ID: 32479170
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of rituximab in primary and secondary glomerulonephritis].
    Insalaco M; Zanoli L; Fatuzzo P; Fiorini F; Granata A
    G Ital Nefrol; 2015; 32(6):. PubMed ID: 26845209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracapillary glomerulonephritis type I with the coexistence of positive anti-GBM and p-ANCA antibodies.
    Toledo Perdomo K; Ortega Salas R; Pérez-Sáez MJ; Esquivias de Motta E; Espinosa Hernández M; López Andreu M; López Rubio F; Aljama García P
    Nefrologia; 2011; 31(1):113-5. PubMed ID: 21270926
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of mammalian target of rapamycin pathway in the pathogenesis of pauci-immune glomerulonephritis.
    Soypacaci Z; Cakmak O; Cakalagoglu F; Gercik O; Ertekin I; Uzum A; Ersoy R; Akar S
    Ren Fail; 2019 Nov; 41(1):907-913. PubMed ID: 31658846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.